Matthew Millard is a pharmacist who is specialized in Pediatrics in Aurora, Colorado. Patients can reach him at 13123 E 16th Ave # B375, Aurora or contact him on 720-777-2501. Active license number of Matthew Millard is PHA0018085 for Pediatrics in Colorado. Matthew Millard is a licensed pharmacist who has demonstrated specialized knowledge and skill in the delivery of patient care services by pharmacists that ensures the safe and effective use of medications for all children from neonates through adolescents.
Complete Profile:
Matthew Millard speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Matthew Millard
Specialization:
Pediatrics
Credentials:
PHARMD
Gender:
Male
Location:
13123 E 16th Ave # B375, Aurora, Colorado, 80045-7106
Phone:
720-777-2501
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Matthew Millard are as mentioned below.
NPI Number:
1427601079
NPI Enumeration Date:
23 Jul, 2019
NPI Last Update On:
23 Jul, 2019
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Matthew Millard are as mentioned below.
Specialization
License Number
State
Status
Pediatrics
PHA0018085
Colorado
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
13123 E 16th Ave # B375, Aurora, Colorado
Zip:
80045-7106
Phone Number:
720-777-2501
Fax Number:
--
Patients can reach Matthew Millard at 13123 E 16th Ave # B375, Aurora, Colorado or can call on phone at 720-777-2501.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.